{
    "clinical_study": {
        "@rank": "114173", 
        "arm_group": [
            {
                "arm_group_label": "RVX000222, 200 mg daily", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study builds on data that high-density lipoprotein (HDL) has a number of potentially\n      beneficial effects including directly modulating glucose metabolism through multiple\n      mechanisms. The primary objective of this study is to determine the effects of RVX000222 on\n      postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or\n      impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test\n      (OGTT)."
        }, 
        "brief_title": "The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Glucose Intolerance", 
                "Prediabetic State"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males aged 18-70 years, inclusive\n\n          -  Body mass index (BMI): 25-40 kg/m2\n\n          -  HDL cholesterol plasma levels: \u22641.4 mmol/L\n\n          -  Pre-diabetes: Either impaired fasting glucose (IFG; 6.1-6.9mmol/L) or impaired\n             glucose tolerance (IGT; 2 hour OGTT glucose 7.8-11.0mmol/L, WHO classification) as\n             measured at Visit 1\n\n          -  No current use or need for prescription or over-the-counter medication within four\n             days of Visit 1\n\n          -  Have given signed informed consent to participate in the study\n\n        Exclusion Criteria:\n\n          -  Identification of any other medical condition requiring immediate therapeutic\n             intervention\n\n          -  Has received any over-the-counter medication including vitamins, herbal, or dietary\n             supplements within four days of Visit 1 unless prior approval from the Investigator\n\n          -  Tobacco use within six months of Visit 1 (including cigarettes, pipes, chewing\n             tobacco)\n\n          -  Elective surgery requiring general anaesthesia during the course of the study\n\n          -  Clinically significant heart disease at Visit 1\n\n          -  Clinically significant abnormal ECG at Visit 1\n\n          -  Evidence of renal impairment defined as serum creatinine >1.5 mg/dL (133 \u03bcmol/L) or\n             creatinine clearance of <60 mL/min\n\n          -  History of hypertension or supine SBP >160mmHg or DBP >95mmHg as measured at Visit 1\n\n          -  Evidence of type 2 diabetes (fasting plasma glucose \u22657.0mmol/L; 2 hour OGTT glucose\n             \u226511.1mmol/L)\n\n          -  Evidence of liver disease defined as aspartate aminotransferase (AST), alanine\n             aminotransferase (ALT) or total bilirubin >1.5 x upper limit of normal (ULN) at Visit\n             1\n\n          -  History of malignancy within past 5 years\n\n          -  History or evidence of drug or alcohol abuse within 12 months of Visit 1\n\n          -  Use of other investigational drugs and/or devices at the time of enrolment, or within\n             30 days of Visit 1\n\n          -  History of non-compliance to medical regimens or unwillingness to comply with the\n             study protocol\n\n          -  Any condition that in the opinion of the Investigators would confound the evaluation\n             and interpretation of the data\n\n          -  Persons directly involved in the execution of the protocol"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01728467", 
            "org_study_id": "RVX222-CS-010", 
            "secondary_id": "Alfred Study No. 409/12"
        }, 
        "intervention": [
            {
                "arm_group_label": "RVX000222, 200 mg daily", 
                "description": "capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days", 
                "intervention_name": "RVX000222", 
                "intervention_type": "Drug", 
                "other_name": "RVX-208"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days", 
                "intervention_name": "Placebo, RVX000222", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Melbourne", 
                    "country": "Australia", 
                    "state": "Victoria", 
                    "zip": "3004"
                }, 
                "name": "Baker IDI Heart and Diabetes Institute 75 Commercial Road,"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2 Randomised, Double-blind, Placebo-controlled, Cross-over Study for the Assessment of Glucose Metabolism Changes With RVX000222 in Individuals With Pre-diabetes", 
        "overall_official": [
            {
                "affiliation": "Baker IDI Heart and Diabetes Institute", 
                "last_name": "Professor Bronwyn Kingwell", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Baker IDI Heart and Diabetes Institute", 
                "last_name": "Dr. Stephen Duffy", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The change in postprandial plasma glucose, defined as area under the glucose curve (AUGC) during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo.", 
            "measure": "Change in plasma glucose following treatment with RVX000222 compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "29-33 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01728467"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in indices of insulin secretion (\u03b2-cell function) and insulin sensitivity during a frequently sampled OGTT following RVX000222 treatment for 29-33 days as compared to placebo.", 
            "measure": "Change in insulin secretion and insulin sensitivity following treatment with RVX000222 compared to placebo", 
            "safety_issue": "No", 
            "time_frame": "29-33 days"
        }, 
        "source": "Resverlogix Corp", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Baker IDI Heart and Diabetes Institute", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Nucleus Network Ltd", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Resverlogix Corp", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}